People

Mark Bamforth

kineticos.comlinkedin.com

Mark Bamforth is published by Kineticos Life Sciences as KAMRA I Investment Committee Member. Mark Bamforth is a General Partner in the Kineticos Anti-Microbial Resistance Accelerator (KAMRA) Fund I. Previously, Mr. Bamforth founded, grew and sold three PE-backed contract development and manufacturing organizations (CDMO); specifically, Arranta Bio, founded in 2019 to focus on the microbiome, which was sold to Recipharm in 2022, Brammer Bio, which was founded in 2015, supporting cell and gene therapies, and was acquired by Thermo Fisher Scientific in 2019, and Gallus Biopharmaceuticals, founded in 2010 to manufacture mAbs, and was sold to Patheon in 2014. Prior to this, Mr. Bamforth was the head of global operations at Genzyme Corporation. Mr. Bamforth serves on the boards of Enterobiotix, Pneumagen, Continuus Pharmaceuticals, Kincell Bio, and Entrepreneurial Scotland. Mr. Bamforth has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.